204 related articles for article (PubMed ID: 33358592)
1. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A
Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592
[TBL] [Abstract][Full Text] [Related]
2. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).
Viúdez A; Carvalho FL; Maleki Z; Zahurak M; Laheru D; Stark A; Azad NS; Wolfgang CL; Baylin S; Herman JG; De Jesus-Acosta A
Oncotarget; 2016 May; 7(18):24950-61. PubMed ID: 26894863
[TBL] [Abstract][Full Text] [Related]
3. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
4. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
5. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Cives M; Ghayouri M; Morse B; Brelsford M; Black M; Rizzo A; Meeker A; Strosberg J
Endocr Relat Cancer; 2016 Sep; 23(9):759-67. PubMed ID: 27552969
[TBL] [Abstract][Full Text] [Related]
6. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G
Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792
[TBL] [Abstract][Full Text] [Related]
7. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
8. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
[TBL] [Abstract][Full Text] [Related]
9. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.
Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J
Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
[TBL] [Abstract][Full Text] [Related]
11. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
13. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
[TBL] [Abstract][Full Text] [Related]
14. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
15. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
16. Should temozolomide be used on the basis of O
Trillo Aliaga P; Spada F; Peveri G; Bagnardi V; Fumagalli C; Laffi A; Rubino M; Gervaso L; Guerini Rocco E; Pisa E; Curigliano G; Fazio N
Cancer Treat Rev; 2021 Sep; 99():102261. PubMed ID: 34332293
[TBL] [Abstract][Full Text] [Related]
17. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
18. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.
Isohookana J; Haapasaari KM; Soini Y; Leppänen J; Karihtala P
Pathol Res Pract; 2018 Jun; 214(6):840-847. PubMed ID: 29735403
[TBL] [Abstract][Full Text] [Related]
19. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
